To determine the extent to which off-target effects generated “hit” phenotypes in our primary screen, we performed a validation screen where we tested each individual siRNA alone for modification of NF-κB responses to TNF in HeLa cells and adenocarcinoma A549 cells. The gene discussed is NFKB1; the disease is adenocarcinoma.